Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Consequences of a "no" vote: from IR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(192)
•••
Comment by craighenryon Jan 18, 2023 1:22pm
88 Views
Post# 35231019

RE:RE:RE:Consequences of a "no" vote: from IR

RE:RE:RE:Consequences of a "no" vote: from IR
zwerp2000 wrote: So i am confused. If xB3 is really worth so much, how come BTI could not find a partner to help develop it and save them? Surely if there was any value to xB3, they could have found someone to partner with, no? Doesn't make sense to have such a valuable asset and have pretty much no one interested in using it after all of these years


Zwerp!  You dont get it.  ONLY JBroke is able to "read between the lines" about XB3.

Big Pharmaceutical companies just couldn't do it.  Their Chief Medical Officers,  Lead scientists,  technicians,  NO ONE could see the value of XB3 because they aren't "smart enough" to "read between the lines" like JBroke!!


Thats why they passed on Bioasis.




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities